Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Teodoro Chisesi"'
Autor:
Brenner Sabando, Andres Orquera, Danilo Navarrete, Jhoana Ramirez, Teodoro Chisesi, Jorge Oliveros-Alvear, Jairo Quinonez
Publikováno v:
HemaSphere, Vol 7, p e64113c3 (2023)
Externí odkaz:
https://doaj.org/article/4f2b260e693d4781899f6e01b3bc2318
Autor:
Teodoro Chisesi
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 31, Pp 51-56 (2009)
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in the Western world and predominantly affects the elderly. Although CLL remains incurable with standard treatments, important progress in treatment, which classically i
Externí odkaz:
https://doaj.org/article/d1bd42120c104fd281119dd2ae018031
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 30, Pp 1-2 (2008)
Externí odkaz:
https://doaj.org/article/3c26c1bebdd84fb99380cfda9f72bb0e
Autor:
Jorge J. Castillo, Luis Villela Villela, Eduardo M. Sotomayor, C. Mahuad, Henry Idrobo, O. Bonell, Fabiola Valvert, Sally Rose Paredes, Fernando Warley, Myriam Rodríguez, Ivan Perdomo, Gregorio Ignacio, Brady E Beltran, Luis Malpica, Lorena Fiad, G. Garate, Nancy Cristaldo, Camila Peña, D.A. Castro Uriol, Maria Elena Cabrera, Victoria Otero, C.S. Chiattone, M.A. Torres Viera, Teodoro Chisesi
Publikováno v:
Hematological Oncology. 37:463-464
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c0273a2f4641aadeda1c0e5b0fe93f9
https://doi.org/10.1002/hon.142_2631
https://doi.org/10.1002/hon.142_2631
Autor:
Giovanni Capnist, Teodoro Chisesi
Publikováno v:
Leukemialymphoma. 3(5-6)
The records of 104 patients (1972-80) with Multiple Myeloma (MM) were reviewed and a staging system was used dividing patients into Low Risk (LR) and High Risk (HR) groups, according to individual factors. Serum-calcium and serum creatinine, haemoglo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820fcc07ff89756362b8e8d7db256557
https://pubmed.ncbi.nlm.nih.gov/27467432
https://pubmed.ncbi.nlm.nih.gov/27467432
Autor:
Myriam Rodríguez, Abel Berrios, Denisse Castro, Maria Elena Cabrera, Camila Peña, Carlos S. Chiattone, Victoria Otero, Fabiola Valvert Gamboa, Raul Gabus, Marialejandra Torres Viera, Teodoro Chisesi, Gregorio Ignacio, Brady E Beltran, Eduardo M. Sotomayor, Gabriel Borelli, Jorge J. Castillo, Sally Rose Paredes
Publikováno v:
Blood. 132:5395-5395
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world and corresponds to a heterogeneous entity, both from the clinical and molecular point of view, being its prognosis of survival very variable The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f93c4fee5ad8f8780349e3faf91410cd
https://doi.org/10.1182/blood-2018-99-113214
https://doi.org/10.1182/blood-2018-99-113214
Autor:
Sally Rose Paredes, Myriam Rodríguez, Maria Elena Cabrera, Victoria Otero, Brady E Beltran, Fabiola Valvert Gamboa, Carlos S. Chiattone, Teodoro Chisesi, Raul Gabus, Gregorio Ignacio, Gabriel Borelli, Denisse Castro, Jorge J. Castillo, Camila Peña, Abel Berrios, Eduardo M. Sotomayor, Marialejandra Torres Viera
Publikováno v:
Blood. 132:2987-2987
Introduction: Diffuse large B-Cell Lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world. The IPI score is a powerful risk-stratification tool in patients with DLBCL. The neutrophil-to-lymphocyte ratio (NLR) has shown to be prognosti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caac22c646635f831cb3f0cd51d08507
https://doi.org/10.1182/blood-2018-99-113246
https://doi.org/10.1182/blood-2018-99-113246
Autor:
Ignazio Majolino, Andrea Gallamini, Fabio Benedetti, Marco Ladetto, Mario Boccadoro, Daniela Drandi, Teodoro Chisesi, Corrado Tarella, Angelo De Blasio, Anna Locasciulli
Publikováno v:
Medical Oncology. 23:359-368
B-CLL patients with resistant/relapsed disease or adverse prognostic factors at presentation are suitable for alternative treatments. In the present pilot study we investigated a novel intensive chemo-immunotherapy approach for high-risk, fludarabine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e7b0d6230368f1e77457e052cdd7e5
https://doi.org/10.1385/mo:23:3:359
https://doi.org/10.1385/mo:23:3:359
Autor:
Paolo G. Gobbi, Vincenzo Pavone, Caterina Stelitano, Alessandro Levis, Teodoro Chisesi, Marina Liberati, Chiara Broglia, Luigi Cavanna, Massimo Federico, Umberto Vitolo, Francesco Merli, Giorgio Lambertenghi Deliliers, Luca Baldini, Gino Santini, Emanuele Angelucci, Roberto Bordonaro
Publikováno v:
Journal of Clinical Oncology. 23:9198-9207
Purpose In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b29d103c8fb759685344c36e2d6904
https://doi.org/10.1200/jco.2005.02.907
https://doi.org/10.1200/jco.2005.02.907
Autor:
Jean Louis Ravetti, Teodoro Chisesi, Alessandra Rubagotti, R. Vimercati, Mauro Spriano, G. Marino, Sandro Nati, Marco Candela, Simona Zupo, Alessandro Polacco, Vittorio Rizzoli, Savina Aversa, Gino Santini, A. M. Congiu, Caterina Patti, Adolfo Porcellini, Valerio Zoli
Publikováno v:
Leukemia & Lymphoma. 45:1141-1147
The aim of the study was to determine the safety and efficacy of the combination of fludarabine (FLU), cyclophosphamide (CY) and mitoxantrone (FLU/CY/MITO) in untreated follicular lymphomas (FL), Sixty patients with newly diagnosed stage II bulky to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b92b3dd1171e8062d83f83b88c79e1
https://doi.org/10.1080/10428190310001623874
https://doi.org/10.1080/10428190310001623874